Updated March 2026 · RehabHive Editorial Team · Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any treatment.
Every 11 minutes, another American dies from an opioid overdose. In 2024, opioid-involved fatalities topped 81,000—making it the deadliest drug crisis in U.S. history. Yet one of the most effective interventions, medication-assisted treatment (MAT), remains dramatically underused: according to SAMHSA, fewer than 25% of people with opioid use disorder receive any form of MAT. If you or someone you love is struggling with opioid or alcohol dependence, understanding how these medications work could literally save a life.
What Is Medication-Assisted Treatment and Why Does It Matter?
Medication-assisted treatment combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. Think of it this way: if addiction were diabetes, MAT would be the insulin—not a crutch, but a medically necessary tool that restores normal brain function while therapy builds long-term coping skills.
The science is unambiguous. A landmark study published by the National Institute on Drug Abuse (NIDA) found that MAT reduces opioid use by 50–80%, cuts overdose deaths nearly in half, and significantly improves treatment retention. Patients on MAT are also 75% less likely to die from any cause compared to those who receive no medication.
Despite these numbers, stigma persists. Some people—and even some treatment centers—insist that using medication to treat addiction is "just replacing one drug with another." That claim, as we'll see, fundamentally misunderstands how these medications interact with the brain.
How Suboxone Works: The Partial Agonist Approach
Suboxone (buprenorphine/naloxone) is the most commonly prescribed MAT medication in the United States. Over 1.6 million Americans currently take it. Here's what makes it different from the opioids it's designed to treat:
Buprenorphine is a partial opioid agonist. It activates the same brain receptors as heroin or fentanyl—but only partially. Imagine a dimmer switch versus a light switch. Full agonists like heroin flip the switch all the way on, flooding the brain with dopamine. Buprenorphine turns the dimmer up just enough to prevent withdrawal and cravings without producing the euphoric "high."
The naloxone component serves as a safety net. If someone tries to dissolve Suboxone and inject it, naloxone activates and immediately blocks opioid effects, triggering withdrawal. Taken as directed (dissolved under the tongue), the naloxone has virtually no effect.
Real scenario: Marcus, 34, had been using fentanyl daily for two years. He'd tried quitting cold turkey three times and relapsed within a week each time—not because he lacked willpower, but because withdrawal symptoms were unbearable and cravings overwhelming. After starting Suboxone through his doctor's office, he stabilized within 48 hours. Twelve months later, he's working full-time and hasn't used fentanyl once. "I finally felt normal," he says. "Not high—just normal."
Cost: Generic buprenorphine/naloxone strips run $100–$300/month without insurance. Most Medicaid plans and private insurers cover it, bringing the copay to $5–$50/month. Many rehab facilities include Suboxone in their treatment programs at no additional cost.
Methadone: The Gold Standard for Severe Opioid Dependence
Methadone has been used to treat opioid addiction since the 1960s—longer than any other MAT medication. It's a full opioid agonist, meaning it fully activates opioid receptors, but does so slowly and steadily over 24–36 hours. This long, even action prevents the spikes and crashes that drive compulsive drug use.
Unlike Suboxone, methadone must be dispensed at federally regulated Opioid Treatment Programs (OTPs). Patients typically start by visiting the clinic daily, earning "take-home" doses as they demonstrate stability. This structure can feel restrictive, but for individuals with severe, long-standing opioid dependence, it provides critical accountability.
The data on methadone is extraordinary. A 2020 meta-analysis in the Cochrane Database of Systematic Reviews found that methadone maintenance therapy reduces illicit opioid use by 33% compared to non-medication approaches and cuts overdose mortality by over 50%. It also reduces criminal activity, HIV transmission, and hepatitis C spread among people who inject drugs.
Cost: Methadone treatment costs approximately $6,500–$7,500 per year (around $125–$150/week), according to SAMHSA. Compare this to the estimated $72,000 annual cost of untreated opioid addiction (emergency rooms, incarceration, lost productivity) and the math speaks for itself. If you're exploring treatment options, browse treatment centers near you that offer methadone programs.
Vivitrol (Naltrexone): Blocking the High Entirely
Vivitrol takes a completely different approach. Where Suboxone and methadone activate opioid receptors (partially or fully), naltrexone is a pure opioid antagonist—it blocks those receptors entirely. If someone on Vivitrol uses heroin or takes an opioid pill, they feel nothing. No high, no euphoria, nothing.
Vivitrol is administered as a once-monthly injection, which eliminates the daily decision to take medication. This can be especially powerful for people who struggle with medication adherence. The extended-release naltrexone formulation maintains steady blood levels for approximately 30 days.
There's one critical caveat: patients must be fully detoxed (7–14 days opioid-free) before receiving Vivitrol. If naltrexone is given while opioids are still in the system, it can precipitate severe, immediate withdrawal. This requirement makes the induction phase more challenging—but once started, Vivitrol's effectiveness rivals that of Suboxone. The X:BOT clinical trial (NIDA-funded, published in The Lancet) found that among patients who successfully initiated treatment, Vivitrol and Suboxone had comparable relapse rates at 24 weeks.
Vivitrol is also FDA-approved for alcohol use disorder, making it the only MAT medication that treats both opioid and alcohol dependence.
Real scenario: Jennifer, 28, completed medical detox and knew from past experience that her cravings hit hardest in weeks 2–6. Her treatment team recommended Vivitrol. "Knowing that even if I slipped, I wouldn't feel anything—that removed the temptation entirely," she explains. After six monthly injections, she transitioned to oral naltrexone and has been in recovery for 14 months.
Cost: Vivitrol injections cost approximately $1,500–$1,800/month without insurance. With coverage, copays typically range from $0–$100. The manufacturer offers a copay assistance program that can reduce costs to $5/month for eligible patients.
Which MAT Medication Is Right? A Practical Comparison
Choosing the right medication depends on individual circumstances—there's no universal "best" option. Here's how the three compare across key factors:
For severe, long-term opioid dependence with a history of multiple relapses: Methadone often provides the most robust stabilization. Its full agonist action provides more complete relief from cravings and withdrawal, and the structured clinic environment adds accountability.
For people who need flexibility and prefer office-based treatment: Suboxone can be prescribed by any qualified physician, nurse practitioner, or physician assistant. No daily clinic visits required. Since 2023, the federal X-waiver requirement has been eliminated—any DEA-registered provider can prescribe buprenorphine.
For highly motivated individuals who have completed detox and want complete opioid blockade: Vivitrol removes the possibility of getting high, which some patients find liberating. The monthly injection also simplifies adherence.
For alcohol use disorder: Naltrexone (oral or Vivitrol) is the primary MAT option, along with acamprosate and disulfiram. Neither Suboxone nor methadone is indicated for alcohol dependence.
Many treatment centers offer comprehensive assessments to determine which medication—if any—best fits your situation. The conversation should always include your treatment history, medical conditions, lifestyle, and personal preferences.
Five Persistent Myths About MAT—and the Evidence That Debunks Them
Myth 1: "You're just replacing one addiction with another."
This is the most damaging myth in addiction medicine. Addiction is characterized by compulsive use despite harm, loss of control, and escalating doses to chase a high. MAT medications, taken as prescribed, produce none of these effects. They stabilize brain chemistry at therapeutic levels. NIDA's official position: "MAT is not the same as substituting one addictive drug for another."
Myth 2: "Real recovery means being completely drug-free."
Nobody tells a person with depression that "real mental health" means stopping antidepressants. Opioid use disorder is a chronic brain condition with well-documented neurological changes. Medication corrects those changes. Abstinence-only approaches have a 90% relapse rate within the first year; MAT cuts that to 40–50%.
Myth 3: "MAT is only for short-term use."
Research shows that longer durations of MAT produce better outcomes. The American Society of Addiction Medicine (ASAM) recommends a minimum of 12 months, and many patients benefit from indefinite maintenance—just as someone with hypertension may take blood pressure medication for life.
Myth 4: "Methadone clinics attract crime and drug dealing."
Studies consistently show that OTPs reduce crime in surrounding areas by stabilizing patients who would otherwise be engaging in drug-seeking behavior. A 2019 study in the Journal of Substance Abuse Treatment found no increase in crime rates near newly opened methadone clinics.
Myth 5: "You can't be in a 12-step program and take MAT."
While some 12-step groups have historically stigmatized MAT, Narcotics Anonymous updated its bulletin in 2016 to clarify that members on medication should not be excluded. Many MAT-friendly meetings now exist, and AA/NA participation combined with MAT shows the strongest recovery outcomes of any approach.
How to Start MAT: The Step-by-Step Process
Starting MAT is more accessible than most people realize. Here's what the process typically looks like:
1. Assessment (Day 1): A provider evaluates your substance use history, medical conditions, mental health, and treatment goals. This can happen in a doctor's office, treatment facility, ER, or even via telehealth.
2. Induction (Days 1–3): For Suboxone, you must be in mild-to-moderate withdrawal before taking your first dose (typically 12–24 hours after your last opioid use). For methadone, induction happens at the clinic with careful dose titration over days to weeks. For Vivitrol, you must be 7–14 days opioid-free.
3. Stabilization (Weeks 1–8): Your provider adjusts the dose until cravings and withdrawal are controlled without side effects. During this phase, regular check-ins are critical.
4. Maintenance (Months to years): Once stabilized, appointments decrease in frequency. Most patients on Suboxone see their provider monthly. Methadone patients may earn up to 28 take-home doses at a time. Vivitrol patients return monthly for their injection.
5. Concurrent therapy: MAT works best when combined with individual counseling, group therapy, and support groups. Medication manages the biological component; therapy addresses the psychological, social, and behavioral dimensions. Research shows the combination reduces relapse rates by an additional 20–30% compared to medication alone.
If cost is a concern, read our guide on how to pay for rehab without insurance—many of the same strategies apply to MAT.
Success Rates and Long-Term Outcomes: What the Research Shows
Let's talk numbers, because they matter:
- Treatment retention: MAT doubles 12-month treatment retention rates compared to behavioral therapy alone (60% vs. 30%, per NIDA)
- Overdose reduction: Buprenorphine reduces overdose death risk by 38%; methadone by 59% (Lancet Psychiatry, 2023)
- Employment: 50% of MAT patients return to full-time employment within 12 months
- Criminal justice: Inmates who start MAT before release are 75% less likely to return to prison within 12 months
- Pregnancy: MAT (specifically buprenorphine or methadone) is the standard of care for pregnant women with opioid use disorder—it reduces preterm birth and neonatal complications
The aha moment for many families is this: MAT doesn't just treat addiction—it treats mortality. Without treatment, opioid use disorder has a fatality rate that rivals many cancers. MAT changes the survival curve dramatically.
For those exploring residential treatment options that incorporate MAT, search treatment centers that list medication-assisted treatment among their services.
Frequently Asked Questions About Medication-Assisted Treatment
How long do you have to stay on Suboxone?
The minimum recommended duration is 12 months, but many patients benefit from longer or indefinite treatment. Research shows that patients who remain on Suboxone for at least 18 months have significantly lower relapse rates than those who taper early. The decision to taper should be made collaboratively with your provider based on stability, support systems, and personal goals.
Can you get high on Suboxone or methadone?
When taken as prescribed and at stable doses, neither medication produces a "high." Suboxone's partial agonist action has a ceiling effect—taking more doesn't increase euphoria beyond a low threshold. Methadone at therapeutic doses creates steady-state levels without the spikes associated with euphoria. Both medications are designed to normalize brain function, not impair it.
Does insurance cover medication-assisted treatment?
Yes. Under the Mental Health Parity and Addiction Equity Act and the Affordable Care Act, most insurance plans—including Medicaid—must cover MAT. The average monthly out-of-pocket cost with insurance is $25–$75 for Suboxone, $0–$50 for methadone (through OTPs), and $0–$100 for Vivitrol. Many manufacturers also offer patient assistance programs.
What are the side effects of MAT medications?
Common side effects of buprenorphine include constipation, headache, nausea, and insomnia—typically mild and resolving within weeks. Methadone may cause sweating, weight gain, and drowsiness. Vivitrol's most common side effects are injection site reactions, nausea, and headache. Serious side effects are rare but should be discussed with your provider.
Can you take MAT medications while pregnant?
Yes—in fact, MAT is the standard of care for pregnant women with opioid use disorder. Buprenorphine and methadone are both FDA-approved for use during pregnancy. Abruptly stopping opioids during pregnancy can cause fetal distress and miscarriage, making supervised MAT the safest option. Vivitrol (naltrexone) is not recommended during pregnancy due to insufficient safety data.
Is MAT available through telehealth?
Yes. Since 2020, federal regulations have allowed buprenorphine prescriptions via telehealth without an in-person visit. This policy was made permanent in 2024. Methadone still requires in-person visits to OTPs, though take-home dose flexibility has expanded. Vivitrol injections must be administered in person.
How does MAT compare to abstinence-only programs?
Head-to-head research consistently favors MAT. The 12-month relapse rate for abstinence-only programs is approximately 85–90%, compared to 40–50% for MAT combined with therapy. The overdose death rate during and after abstinence-only treatment is also significantly higher, because tolerance drops during abstinence, making relapse extremely dangerous.
Need help finding a treatment center that offers MAT? Call RehabHive at (844) 946-1431 or browse facilities to find programs with medication-assisted treatment near you.
